CPX-351 and Gemtuzumab Ozogamicin in Treating Patients With Relapsed Acute Myeloid Leukemia
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03904251|
Recruitment Status : Recruiting
First Posted : April 5, 2019
Last Update Posted : May 12, 2022
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Acute Myelogenous Leukemia||Drug: Gemtuzumab Ozogamicin Drug: Liposome-encapsulated Daunorubicin-Cytarabine||Phase 1|
I. To determine the phase II dose of the combination liposome-encapsulated daunorubicin-cytarabine (CPX-351) plus gemtuzumab ozogamicin (GO) by means of estimating maximum tolerated dose (MTD) in participants with relapsed acute myeloid leukemia (AML).
I. To estimate the remission rate (complete remission plus complete remission with incomplete hematologic recovery) of participants in the MTD cohort who receive CPX-351 plus GO.
II. To evaluate CPX-351 plus GO as a bridge to allogeneic hematopoietic stem cell transplantation (HSCT) in participants with relapsed AML.
III. To estimate the duration of remission. IV. To evaluate for toxicity by means of Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.
V. To evaluate for the development of veno-occlusive disease at any point during the study in participants treated with CPX-351 plus GO.
VI. To evaluate time to return of normal hematopoiesis after induction therapy. VII. To evaluate 30- and 60-day survival.
I. To evaluate if there is a difference in remission rate based on CD33 splicing single nucleotide polymorphism (SNP) genotype (CC, TC, or TT) in participants receiving CPX-351 plus GO.
II. To evaluate the impact that leukemia cell multidrug resistance activity have on achieving remission after treatment with CPX-351 plus GO.
III. To evaluate the possible associations of participant constitutional genotype, leukemia genotype, and response to therapy.
IV. To evaluate the possible associations of participant ribonucleic acid (RNA) expression, leukemia RNA expression, and response to therapy.
OUTLINE: This is a dose-escalation study of gemtuzumab ozogamicin when given in combination with liposome-encapsulated daunorubicin-cytarabine.
INDUCTION: Patients receive liposome-encapsulated daunorubicin-cytarabine intravenously (IV) over 90 minutes on days 1, 3, and 5, and gemtuzumab ozogamicin IV over 2 hours on day 7 in the first cohort of study participants, days 4 and 7 in the second cohort of study participants, or days 1, 4, and 7 in the third cohort of study participants, in the absence of disease progression or unacceptable toxicity. The dose expansion cohort will receive the above treatment schedule that is determined to be the maximum tolerated dose.
CONSOLIDATION: Patients who achieve complete remission (CR)/CR with incomplete hematologic recovery (CRi) receive consolidation therapy at the discretion of the treating physician and/or proceed to allogeneic HSCT.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||33 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase Ib Trial With Dose Expansion Evaluating CPX-351 Plus Gemtuzumab Ozogamicin for Relapsed Acute Myelogenous Leukemia|
|Actual Study Start Date :||July 18, 2019|
|Estimated Primary Completion Date :||July 1, 2023|
|Estimated Study Completion Date :||July 1, 2024|
Experimental: Treatment (CPX-351, gemtuzumab ozogamicin)
INDUCTION: Patients receive liposome-encapsulated daunorubicin 44mg/m2 - cytarabine 100mg/m2 IV over 90 minutes on days 1, 3, and 5, and gemtuzumab ozogamicin 3 mg/m2 (max 4.5 mg) IV over 120 minutes on day 7, or days 4 and 7, or days 1, 4, and 7 in the absence of disease progression or unacceptable toxicity.
CONSOLIDATION: Patients who achieve CR/CRi receive consolidation therapy at the discretion of the treating physician and/or proceed to allogeneic HSCT.
Drug: Gemtuzumab Ozogamicin
Drug: Liposome-encapsulated Daunorubicin-Cytarabine
- Maximum tolerated dose (MTD) [ Time Frame: Up to day 42 ]MTD is defined as the cohort of participants one cohort below the cohort that develop dose-limiting toxicity (DLT) in at least 2 participants.
- Objective response rate (ORR) [ Time Frame: Up to day 42 ]Objective response, including complete remission (CR) plus complete remission with incomplete hematologic recovery (CRi), after induction therapy will be measured using the International Working Group (IWG) Response Criteria in acute myeloid leukemia (AML).
- Proportion of participants who go on to receive allogeneic hematopoietic cell transplantation (HSCT) after achieving CR/CRi [ Time Frame: Up to 18 months ]The proportion of patients who receive an allogeneic HSCT following a CR/CRi response will be reported along with an exact 95% confidence interval.
- Duration of remission [ Time Frame: Up to 18 months ]Evaluated in participants that achieve CR/CRi, and defined as number of days that elapse from first day CR/CRi to the first day that bone marrow blasts >= 5%. The median duration of remission will be reported in patients who achieved CR/CRi, along with the corresponding range.
- Incidence of toxicities [ Time Frame: Up to day 42 ]Measured by the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.
- Diagnosis of veno-occlusive disease (VOD) [ Time Frame: Up to 18 months ]The diagnosis of veno-occlusive disease is based on the Baltimore criteria: Bilirubin > 2.0 mg/dL, plus, painful hepatomegaly, ascites, and weight gain > 5% basal since initiating therapy with gemtuzumab ozogamicin (GO). The proportion of patients who develop VOD will be reported along with an exact 95% confidence interval.
- Time to return of normal hematopoiesis [ Time Frame: From day 1 of induction, assessed up to 18 months ]Defined as the number of days from day 1 of induction to ANC (absolute neutrophil count) >= 1000/uL (upper limit) and platelet count >= 100,000/uL. Will be reported along with the corresponding range.
- Number of participants deceased at day 30 and day 60 [ Time Frame: At 30 and 60 days following the start of induction ]Mortality is defined as death having occurred in any participant that receives at least one dose of experimental therapy. Kaplan-Meier methods will estimate the overall survival at day 30 and day 60 following the start of induction. The survival estimate at these two time points will be reported along with a 95% confidence interval.
- Genotype at CD33 splicing single nucleotide polymorphism (SNP) RS12459419 [ Time Frame: Up to 18 months ]Determined by whole exome sequencing and confirmatory genotyping.
- Multidrug resistance activity of leukemia cell P-glycoprotein (Pgp) [ Time Frame: Up to 18 months ]Will be determined by the flow cytometry mean fluorescence intensity (MFI) of the efflux of the fluorescent dye DiOC2 (Diethyloxacarbocyanine iodide) (by malignant cells. Will be assessed by dye efflux assay as described by Walter et al. 2003.
- Multidrug resistance activity of leukemia cell multidrug resistance protein 1 (MRD1) [ Time Frame: Up to 18 months ]Will be determined by the flow cytometry efflux MFI of the efflux of the fluorescent dye 5-carboxy-2?,7?-dichlorofluorescein diacetate (CDCF) by malignant cells. Will be assessed by dye efflux assay as described by Walter et al. 2003.
- Exome sequencing analysis [ Time Frame: Up to 18 months ]Tumor deoxyribonucleic acid (DNA) and participant DNA will be measured via Illumina HiSeq3000 sequencing platform to evaluate for associations between participant constitutional genotype (buccal swab sample at enrollment), leukemia genotype (bone marrow aspirate at enrollment and upon relapse), and response to therapy.
- Ribonucleic acid (RNA) sequencing analysis [ Time Frame: Up to 18 months ]Tumor RNA and participant RNA will be measured via RNA sequencing technique.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Bone marrow blasts >= 5% that develops after remission, no restriction on prior number of relapses or regimens
- Eastern Cooperative Oncology Group (ECOG) 0-2
- At least a 3-month duration of remission prior to relapse
- Participants with relapse after allogeneic transplantation are included
- Up to 1 cycle of hypomethylating agent monotherapy at time of relapse is allowed, must be discontinued at least 14 days prior to start of salvage induction
- Serum total bilirubin =< 2.0 mg/dL, unless considered due to Gilbert?s disease or leukemia involvement
- Aspartate aminotransferase (AST), alanine aminotransferase (ALT) =< 3 times the upper limit of normal, unless considered due to leukemia involvement
- Alkaline phosphatase =< 3 times the upper limit of normal, unless considered due to leukemia involvement
- Serum creatinine =< 2.0 mg/dL, or creatinine clearance > 40 mL/min based on Cockcroft-Gault glomerular filtration rate (GFR)
- Ability to give full informed consent on their own
- Females of reproductive potential (postmenopausal for less than 24 consecutive months) must have a negative pregnancy
- Currently receiving targeted therapy for FLT3 (cytokine receptor tyrosine kinase class III), IDH1, or IDH2 (isocitrate dehydrogenase, 1, 2) mutations and intent to continue use; prior use of targeted therapy for such mutations is allowed, but agents should be discontinued 1 week prior to enrollment
- Acute promyelocytic leukemia
- Second malignancy that would limit survival by less than 2 years
- New York Heart Association class III or VI
- Left ventricular ejection fraction < 50%
- History of coronary stent placement that requires mandatory continuation of dual-antiplatelet therapy
- History of Wilson?s disease or other copper handling disorders
- Hypersensitivity to cytarabine, daunorubicin, or liposomal products
- Active invasive fungal infection
- Active bacterial or viral infection manifesting as fevers or hemodynamic instability within the past 72 hours
- Lifetime cumulative daunorubicin-equivalent anthracycline dose > 368 mg/m^2
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03904251
|Contact: Caspian Oliai, MD||310-206-8477 ext email@example.com|
|Contact: Martina Roos, PharmD, PhD||310 firstname.lastname@example.org|
|United States, California|
|UCLA / Jonsson Comprehensive Cancer Center||Recruiting|
|Los Angeles, California, United States, 90095|
|Contact: Vladimir Kustanovitch 310-206-5756 VKustanovich@mednet.ucla.edu|
|Contact: Caspian Oliai, MD COliai@mednet.ucla.edu|
|Principal Investigator: Caspian Oliai|
|UC Irvine Health/Chao Family Comprehensive Cancer Center||Not yet recruiting|
|Orange, California, United States, 92868|
|Contact: Deepa Jeyakumar 888-544-8235 email@example.com|
|Principal Investigator: Deepa Jeyakumar|
|University of California Davis Comprehensive Cancer Center||Not yet recruiting|
|Sacramento, California, United States, 95817|
|Contact: Brian A. Jonas 916-734-3772 firstname.lastname@example.org|
|Principal Investigator: Brian A. Jonas|
|University of California San Diego||Not yet recruiting|
|San Diego, California, United States, 92103|
|Contact: Matthew J. Wieduwilt 858-657-7000 email@example.com|
|Principal Investigator: Matthew J. Wieduwilt|
|UCSF Medical Center-Mount Zion||Not yet recruiting|
|San Francisco, California, United States, 94115|
|Contact: Lloyd E. Damon 415-353-2737 firstname.lastname@example.org|
|Principal Investigator: Lloyd E. Damon|
|Principal Investigator:||Caspian Oliai, MD||UCLA / Jonsson Comprehensive Cancer Center|
|Responsible Party:||Jonsson Comprehensive Cancer Center|
|Other Study ID Numbers:||
NCI-2019-00701 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
18-001419 ( Other Identifier: UCLA / Jonsson Comprehensive Cancer Center )
|First Posted:||April 5, 2019 Key Record Dates|
|Last Update Posted:||May 12, 2022|
|Last Verified:||May 2022|
|Studies a U.S. FDA-regulated Drug Product:||Yes|
|Studies a U.S. FDA-regulated Device Product:||No|
|Product Manufactured in and Exported from the U.S.:||Yes|
Leukemia, Myeloid, Acute
Neoplasms by Histologic Type
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Topoisomerase II Inhibitors
Antineoplastic Agents, Immunological